GRI Bio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| Operating income | -$12.0M | -$8.2M | -$11.4M | -$2.2M | -$9.3M |
| Operating expenses | $12.0M | $8.2M | $11.4M | $2.2M | $9.3M |
| Cash from operations | -$10.2M | -$8.6M | -$9.0M | -$1.1M | -$8.3M |
| Capital expenditure | $3,000 | $0 | $8,000 | $3,000 | $0 |
| Free cash flow | -$10.2M | -$8.6M | -$9.0M | -$1.1M | -$8.3M |
| Total assets | $8.7M | $5.7M | $3.0M | $383,000 | $8.3M |
| Total liabilities | $2.7M | $1.7M | $2.7M | $2.0M | $2.5M |
Shares outstanding 1.8M · Free float 13.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.